Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer-Reference-Cited by-同舟云学术

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer

Published:2017-09-13 Issue: Volume:8 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Akpo Esse I. H.,Jansen Irshaad R.,Maes Edith,Simoens Steven

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference62 articles.

1. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;Eur. J. Cancer,2011

2. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours;Aapro;Eur. J. Cancer,2006

3. PMI6: estimating and comparing resource use and cost of G-CSF use in chemotherapy with the activity-based costing (ABC) method in three settings;Annemans;Value Health,2001

4. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia;Bodey;Ann. Intern. Med.,1966

5. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study;Bonadonna;BMJ,2005

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, safety, and cost-effectiveness of pegylated PEG-rhg-CSF in pediatric patients receiving high-intensity chemotherapy: results from a phase II study;Frontiers in Pharmacology;2024-07-17

2. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study;Cancer Control;2023-01-04

3. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany;Supportive Care in Cancer;2022-09-08

4. Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women With Breast Cancer in China: Results Based on Real-World Data;Frontiers in Pharmacology;2022-02-03

5. The Use of Expert Elicitation among Computational Modeling Studies in Health Research: A Systematic Review;Medical Decision Making;2021-10-25